Biden has gotten somewhat better from his covid case and did some unpaid drug promotion earlier this week.
Millions of Americans have used Paxlovoid [sic] — P a xlovid, excuse me — Paxl o vid. (Laughs.) I tell you what: I think it’s — I used it. (Laughter.) No — Paxlovid, including me.
This lifesaving drug reduces risk of hospitalization and death from COVID-19 by about 90 percent.
Again, it’s free, safe, and easy to take. And we’ve moved quickly to make it widely available, including the thousands of convenient test-to-treat sites where you can get tested and, if you need it, Paxlovid is at — ready right then and there when you make your visit.
Again, go to COVID.gov to find where test-to-treat sites are that are near you.
Not to belittle paxlovid’s success as a treatment, but here’s a quick reminder that when the government says “free”, in this case it means $8B in the last 3 months.
Pfizer’s Covid vaccine brought in $8.8 billion in revenue for the second quarter, while sales of Paxlovid totaled $8.1 billion. The company maintained its 2022 sales guidance for the vaccine of $32 billion and is still expecting $22 billion for Paxlovid.
More info coming out on this election manipulation.
More details and commentary
Pfizer’s decision in late October 2020 to shut down processing of lab samples in its vaccine clinical trial until the day after the election. William Gruber, Pfizer SVP of vaccines, admitted to this extraordinary action of Pfizer’s on November 9, 2020 in an interview
Really? I mean, seriously? After nearly 2 and a half years of bitching about how Trump didnt take it seriously enough, they’re now flopping to claim he had too much urgency?
Soon after President Trump won the presidential election in November, British drugmaker GSK brought an unusual claim to federal prosecutors in Manhattan, according to people familiar with the matter.
A senior GSK scientist, who formerly worked at rival Pfizer, had told GSK colleagues that Pfizer delayed announcing the success of its Covid vaccine in 2020 until after that year’s election.
The U.S. attorney’s office in Manhattan has interviewed at least two people in connection with the allegation, including a GSK executive who took notes of a conversation with the former Pfizer scientist, according to one of the people familiar with the matter.
The scientist, Phil Dormitzer, led Pfizer’s viral vaccine research and development before moving to GSK in 2021. He has since left GSK, and his attorney is among those who have spoken to prosecutors.
